Gene expression in blood is associated with risperidone response in children with autism spectrum disorders

L. Lit, Frank R Sharp, K. Bertoglio, Boryana Stamova, Bradley Ander, A. D. Sossong, R. L. Hendren

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Children with autism spectrum disorders (ASDs) often have severe behavioral problems. Not all children with these problems respond to atypical antipsychotic medications; therefore, we investigated whether peripheral blood gene expression before treatment with risperidone, an atypical antipsychotic, was associated with improvements in severe behavioral disturbances 8 weeks following risperidone treatment in 42 ASD subjects (age 112.7±51.2 months). Exon expression levels in blood before risperidone treatment were compared with pre-post risperidone change in Aberrant Behavior Checklist-Irritability (ABC-I) scores. Expression of exons within five genes was correlated with change in ABC-I scores across all risperidone-treated subjects: GBP6, RABL5, RNF213, NFKBID and RNF40 (α<0.001). RNF40 is located at 16p11.2, a region implicated in autism and schizophrenia. Thus, these genes expressed before treatment were associated with subsequent clinical response. Future studies will be needed to confirm these results and determine whether this expression profile is associated with risperidone response in other disorders, or alternative antipsychotic response within ASD.

Original languageEnglish (US)
Pages (from-to)368-371
Number of pages4
JournalPharmacogenomics Journal
Volume12
Issue number5
DOIs
StatePublished - Oct 2012

Fingerprint

Risperidone
Gene Expression
Antipsychotic Agents
Checklist
Exons
Therapeutics
Autistic Disorder
Genes
Autism Spectrum Disorder
Schizophrenia

Keywords

  • atypical antipsychotic
  • autism
  • gene expression
  • risperidone

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. / Lit, L.; Sharp, Frank R; Bertoglio, K.; Stamova, Boryana; Ander, Bradley; Sossong, A. D.; Hendren, R. L.

In: Pharmacogenomics Journal, Vol. 12, No. 5, 10.2012, p. 368-371.

Research output: Contribution to journalArticle

@article{c15a3cb697d5420db1ee38c4fa96029a,
title = "Gene expression in blood is associated with risperidone response in children with autism spectrum disorders",
abstract = "Children with autism spectrum disorders (ASDs) often have severe behavioral problems. Not all children with these problems respond to atypical antipsychotic medications; therefore, we investigated whether peripheral blood gene expression before treatment with risperidone, an atypical antipsychotic, was associated with improvements in severe behavioral disturbances 8 weeks following risperidone treatment in 42 ASD subjects (age 112.7±51.2 months). Exon expression levels in blood before risperidone treatment were compared with pre-post risperidone change in Aberrant Behavior Checklist-Irritability (ABC-I) scores. Expression of exons within five genes was correlated with change in ABC-I scores across all risperidone-treated subjects: GBP6, RABL5, RNF213, NFKBID and RNF40 (α<0.001). RNF40 is located at 16p11.2, a region implicated in autism and schizophrenia. Thus, these genes expressed before treatment were associated with subsequent clinical response. Future studies will be needed to confirm these results and determine whether this expression profile is associated with risperidone response in other disorders, or alternative antipsychotic response within ASD.",
keywords = "atypical antipsychotic, autism, gene expression, risperidone",
author = "L. Lit and Sharp, {Frank R} and K. Bertoglio and Boryana Stamova and Bradley Ander and Sossong, {A. D.} and Hendren, {R. L.}",
year = "2012",
month = "10",
doi = "10.1038/tpj.2011.23",
language = "English (US)",
volume = "12",
pages = "368--371",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Gene expression in blood is associated with risperidone response in children with autism spectrum disorders

AU - Lit, L.

AU - Sharp, Frank R

AU - Bertoglio, K.

AU - Stamova, Boryana

AU - Ander, Bradley

AU - Sossong, A. D.

AU - Hendren, R. L.

PY - 2012/10

Y1 - 2012/10

N2 - Children with autism spectrum disorders (ASDs) often have severe behavioral problems. Not all children with these problems respond to atypical antipsychotic medications; therefore, we investigated whether peripheral blood gene expression before treatment with risperidone, an atypical antipsychotic, was associated with improvements in severe behavioral disturbances 8 weeks following risperidone treatment in 42 ASD subjects (age 112.7±51.2 months). Exon expression levels in blood before risperidone treatment were compared with pre-post risperidone change in Aberrant Behavior Checklist-Irritability (ABC-I) scores. Expression of exons within five genes was correlated with change in ABC-I scores across all risperidone-treated subjects: GBP6, RABL5, RNF213, NFKBID and RNF40 (α<0.001). RNF40 is located at 16p11.2, a region implicated in autism and schizophrenia. Thus, these genes expressed before treatment were associated with subsequent clinical response. Future studies will be needed to confirm these results and determine whether this expression profile is associated with risperidone response in other disorders, or alternative antipsychotic response within ASD.

AB - Children with autism spectrum disorders (ASDs) often have severe behavioral problems. Not all children with these problems respond to atypical antipsychotic medications; therefore, we investigated whether peripheral blood gene expression before treatment with risperidone, an atypical antipsychotic, was associated with improvements in severe behavioral disturbances 8 weeks following risperidone treatment in 42 ASD subjects (age 112.7±51.2 months). Exon expression levels in blood before risperidone treatment were compared with pre-post risperidone change in Aberrant Behavior Checklist-Irritability (ABC-I) scores. Expression of exons within five genes was correlated with change in ABC-I scores across all risperidone-treated subjects: GBP6, RABL5, RNF213, NFKBID and RNF40 (α<0.001). RNF40 is located at 16p11.2, a region implicated in autism and schizophrenia. Thus, these genes expressed before treatment were associated with subsequent clinical response. Future studies will be needed to confirm these results and determine whether this expression profile is associated with risperidone response in other disorders, or alternative antipsychotic response within ASD.

KW - atypical antipsychotic

KW - autism

KW - gene expression

KW - risperidone

UR - http://www.scopus.com/inward/record.url?scp=84866742795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866742795&partnerID=8YFLogxK

U2 - 10.1038/tpj.2011.23

DO - 10.1038/tpj.2011.23

M3 - Article

C2 - 21647175

AN - SCOPUS:84866742795

VL - 12

SP - 368

EP - 371

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 5

ER -